Recap: Milestone Pharmaceuticals Q3 Earnings
Portfolio Pulse from Benzinga Insights
Milestone Pharmaceuticals (NASDAQ:MIST) reported Q3 earnings with an EPS of $-0.35, beating estimates by 7.89% but with a revenue decrease of $1.50 million from the previous year. Last quarter's EPS beat resulted in a 3.94% share price drop the following day.
November 13, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Milestone Pharmaceuticals reported a better-than-expected Q3 EPS but saw a decrease in revenue compared to last year. Previous earnings beat led to a stock price decline.
While MIST beat EPS estimates, the decrease in revenue and historical stock price drop following last quarter's earnings beat suggest a potential negative short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100